Compare Enveric Biosciences Inc (ENVB) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nasdaq Inc — how do they compare? Enveric Biosciences Inc trades at $1.6 (market cap $6.20M), while Nasdaq Inc trades at $95.23 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 8566.1× Enveric Biosciences Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NDAQ | |
|---|---|---|
Market Cap | $6.20M | $53.11B |
Sector | Health | Financials |
52-Week High | $17.40 | $100.98 |
52-Week Low | $1.27 | $76.85 |
Enterprise Value | $1.30M | $59.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Nasdaq (NDAQ) trades at $95.62, up 1.09% today, with strong technical momentum and consistent earnings beats. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. The company announced the acquisition of LeveL Markets, advancing its always-on markets strategy, and maintains a bullish analyst consensus.
Outlook remains positive with a consensus price target of $109.20, offering ~14% upside. Risks include market volatility sensitivity and integration challenges from acquisitions. Solid profitability and strategic growth initiatives support a favorable investment case, though macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
